Medications Contraindicated in Pregnancy and New FDA Labeling Standards
Regarding medications in pregnancy, clinicians and patients were often confused by the meaning of the pregnancy risk categories because, according to the FDA, it was overly simplistic, led to misinformation, and did not adequately address the available information.
Understanding Category C Classification
As noted in medical literature, Category C is the confusing category. A medication gets this classification if there is insufficient data on its use during pregnancy. Consequently, it could be safe or probably safe, or it could be potentially harmful.
Implementation of the New Labeling System
The labeling changes go into effect on June 30, 2015. The new labeling system allows better patient-specific counseling and informed decision making for pregnant women seeking medication therapies.
While the new labeling improves the old format, it still does not provide a definitive “yes” or “no” answer in most cases. Because of this, clinical interpretation is still required on a case-by-case basis.
Guidelines for Implementation and Scope
The transition to the new system is organized based on product type and approval date:
| Product Category | Labeling Change Status |
| Prescription drugs and biologic products submitted after June 30, 2015 | Will use the new format immediately |
| Prescription drugs approved on or after June 30, 2001 | Will be phased in gradually |
| Over-the-counter (OTC) medicines | Labeling for over-the-counter (OTC) medicines will not change; OTC drug products are not affected by the final rule. |
This systematic update aims to refine the information provided to healthcare providers, although practitioners should still refer to established references such as High-Yield Embryology and relevant clinical databases for the most accurate dose information.